Get to know our clinical trials

Phase II clinical trial to evaluate the efficacy and safety of Raludotatug Deruxtecan (R-DXd) in advanced or metastatic solid tumors

THE MAIN OBJECTIVE IS TO EVALUATE THE EFFICACY OF R-DXD TREATMENT AS MEASURED BY ORR AS ASSESSED BY THE INVESTIGATOR.

Imagen del Dr. Antonio González Martín, director del Departamento de Oncología Médica de la Clínica Universidad de Navarra
Dr. Antonio González Curriculum
Director Medical Oncology Department
Madrid headquarters
Cancer Center
Gynecologic Cancer Area
Status
In recruitment
headquarters
Madrid
Early phase

Technical Summary

  • PHASE II, MULTICENTER, OPEN-LABEL, PANTUMORAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF RALUDOTATUG DERUXTECAN (R-DXD) IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS.
  • Code EudraCT: 2024-513307-13-00
  • Protocol number: DS6000-126
  • Promoter: Daiichi Sankyo Inc
  • Molecule/Drug: Raludotaug deruxtecan

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

Imagen de un icono azul con un fonendoscopio o estetoscopio.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial

I want to make an appointment
Imagen de un icono azul de un registro en el informe médico.

Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.

I WANT TO REQUEST A SECOND OPINION